Sep 2025 23 The Board of Directors Approves the Half-Yearly Financial Report at 30 June 2025 (Price sensitive) – Courtesy English Translation
Aug 2025 18 Philochem AG Announces Completion of Antitrust Clearance and Closing of the OncoACP3 Licensing Agreement with RayzeBio, a Bristol Myers Squibb Company, With a Potential Value of up to $1.35 Billion Plus Royalties
